Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodialfiltation: a crossover trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-000042-31-AT

Enrollment

Registered

2008-08-18

Start date

2008-09-04

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodiafiltarion: a crossover trial

Interventions

Trade Name: Argatra Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Heparin Immuno Pharmaceutical Form: Intravenous infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) aged over 18 b) requiring continous renal replacement therapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: a) severe liver dysfunction b) suffering from heprin-induced thrombocytopenia c) known hypersensitivity to argatroban or one of its ingredients d) pregnant or nursing women

Design outcomes

Primary

Measure	Time frame
Main Objective: Comparison of duration of filter life during venovenous haemodiafiltration with anticoagulation with argatroban and prostacyclin or unfractionated heparin and prostacyclin;Secondary Objective: ;Primary end point(s): duration of filter life span during continous venovenous haemodiafiltration	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026